Trials / Terminated
TerminatedNCT06435039
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of APL-1501 ER Capsules Compared to APL-1202 IR Tablets in Healthy Volunteers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Syneos Health · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL-1202 | APL-1202 IR tablets. |
| DRUG | APL-1501 | APL-1501 ER capsules. |
Timeline
- Start date
- 2024-06-21
- Primary completion
- 2024-07-16
- Completion
- 2024-07-16
- First posted
- 2024-05-30
- Last updated
- 2025-01-31
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06435039. Inclusion in this directory is not an endorsement.